A landmark study reveals that KMA and LMA selectively identify malignant plasma cells while sparing normal antibody-producing cells, addressing key efficacy and safety gaps in myeloma, AL amyloidosis and post BCMA relapse.

Stop costly biologic failures. This masterclass reveals high-throughput strategies to optimize antibody leads upfront.

Scientists have identified a new schizophrenia biomarker and potential peptide treatment that could target cognitive symptoms caused by the condition.

Scientists have discovered how an imbalance in gut bacteria can accelerate chronic kidney disease, with early findings pointing to a potential drug that could interrupt the damaging cycle and improve outcomes.

Experimental Parkinson’s drug PRI-101 has shown promising preclinical results, effectively targeting and disassembling toxic α-synuclein protein aggregates that drive neurodegeneration.

Scientists have identified a key link between blood inflammation and immune suppression in bladder cancer, helping explain why some patients do not respond to immunotherapy.

LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.

Engineered probiotic bacteria that can deliver cancer-fighting drugs directly to tumours have shown promising results in mice, offering a potential new approach to targeted cancer therapy.

Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.